Objective To investigate the therapeutic mechanism of Dingkun Dan(DKD)in polycystic ovary syndrome(PCOS)by examining the effects of microRNA-30d-5p on ovarian granulosa cells(GCs).Methods A PCOS rat model was established using dehydroepiandrosterone(DHEA).Normal rat GCs and PCOS rat GCs were cultured in vitro and divided into four groups:blank control group,model group,low-dose DKD group,and high-dose DKD group.After grouping,GCs viability was assessed using the methyl thiazolyl tetrazolium(MTT)assay,GCs apoptosis was analyzed by flow cytometry,and the gene expression of transforming growth factor β1(TGF-β1),Smad2,Smad3,and microRNA-30d-5p in GCs was measured by real-time polymerase chain reaction(RT-PCR),protein expression of TGF-β1,Smad2,and Smad3 in GCs was detected by Western Blot.Results Compared with the blank control group,the model group exhibited significantly decreased GCs viability,increased GCs apoptosis,upregulated mRNA and protein expression of TGF-β1,Smad2,and Smad3,and downregulated microRNA-30d-5p expression,the differences were statistically significant(P＜0.01).Compared with the model group,both low-and high-dose DKD groups showed increased GCs viability,reduced GCs apoptosis,downregulated mRNA and protein levels of TGF-β1 Smad2 and Smad3,elevated microRNA-30d-5p expression,and the differences were statistically significant(P＜0.05 or P＜0.01).Conclusion DKD promotes GCs proliferation by targeting Smad2 via microRNA-30d-5p,suggesting a potential therapeutic role in PCOS-related ovulatory dysfunction.

Objective To investigate the expression of intercellular adhesion molecule 1(ICAM-1)in patients with diabetic foot ulcer(DFU)and its correlation with inflammatory cytokines.Methods A total of 152 patients with DFU(DFU group)and 133 patients with type 2 diabetes mellitus(T2DM group)admitted to our hospital from January 2021 to December 2022 were selected as the study group.120 healthy people matched in age and sex were set as the control group(NC group).Pearson correlation analysis was applied to analyze the correlation between serum ICAM-1 and wagner grade in DFU patients.Results HbA1c,TG,ICAM-1,C-RP,TNF-α,IL-6,IL-18,IL-1β in NC,T2DM and DFU groups gradually increased,but HDL-C gradually decreased(P＜0.05).Pearson correlation analysis showed that serum ICAM-1 was positively associated with C-RP and TNF-α,IL-6,IL-18,IL-1β and wagner grading in DFU patients(P＜0.01).Logistic regression analysis showed that ICAM-1,C-RP,HbA1c and IL-18 were the influencing factors of DFU.Conclusion High levels of serum ICAM-1 in DFU patients are closely related to inflammatory factors and Wagner grading,which helps to identify the severity of the condition.

Objective:To observe the effect on renal function and hemodynamics of pancreatic kininogenase in patients with clinical diabetic nephropathy(DN,Ⅳ Period).Methods: 145 patients with clinical diabetic nephropathy(DN,Ⅳ Period) were divided into the observation group (75 cases) and the control group (70 cases) as random method. The control group was given conventional treatment, and the observation group was given pancreatic kininogenase based on the conventional treatment. After 8 weeks, to observe and analyze the changes of renal function indexes and hemodynamics indexes of the two groups.Results:After treatment, the serum creatinine(SCr), blood urea nitrogen(BUN), Serum Cys C(CysC) and urinary albumin excretion rate(UAER) of observation group were obviously decreased compared with that before treatment; the Cys C, UAER of control group also were obviously decreased, but SCr, BUN of control group had no significant changes compared with that before treatment; and all indexes of the observation group were lower than those of the control group, with significant differences (t=4.2744, t=3.0832,t=6.8261,t=8.0936;P<0.05). After treatment, the systolic pressure(SBP), diastolic blood pressure(DBP) and resistance index(RI) of two groups were decreased; both of peak systolic blood flow(PSV) and end-diastolic blood flow velocity(EVD) were increased, and the change ranges of every index of the observation group were improved more than those in the control group, with significant difference (t=5.6270,t=6.2009,t=5.0926,t=4.764,t=3.1844;P<0.05). Conclusion: Pancreatic kininogenase has the clear effect on protecting renal function in the treatment of clinical diabetic nephropathy(Ⅳ Period), and it can reduce urinary albumin excretion and improve hemodynamics.